title: [Are the properties of peripheral blood lymphocytes of patients with prostate cancer connected with the efficiency of radiation therapy?].
abstract: The genome damage (frequency of cells with micronuclei and chromosome aberrations), concentration of reactive oxygen forms (ROS), markers of lymphocytes activation, expression of proliferation (CD69, Ki67) and proapoptotic antigen (CD95), as well as the ability to adaptive response have been investigated in blood lymphocytes of healthy donors and patients with prostate gland cancer. The influence of hormone-therapy on lymphocytes properties and connection between the parameters studied with the effectiveness of treatment, which was estimated by the level of prostate specific antigen (PSA), have been investigated. It was discovered that the genome damage to the patients with prostate gland cancer lymphocytes does not differ from control. The increase of the ROS level and decrease of radiosensitivity (irradiation of isolated lymphocytes in vitro at a dose of 1 Gy) are observed but they are insignificant. The content of the cells expressing CD69 and CD95 markers doesn't change but the expression of proliferative activity marker Ki67 in cells decreases. Radiosensitivity of lymphocytes in patients with prostate gland cancer correlates with the CD95 markers expression--a higher radio sensitivity points to their predisposition to apoptotic death. The expression of the markers studied depends on the oxidative status--a high ROS level suppresses their expression. The hormone therapy applied before radiotherapy leads to the increase in radiosensitivity and decrease in ROS. As the MN test shows, the ability to adaptive response of the lymphocytes in patients with prostate gland cancer is increased as compared with lymphocytes of healthy donors but it is insignificant; moreover, hormones do not influence the ability to the adaptive response. The high oxidative status further the formation of the adaptive response. We suppose that the discovered correlation between the initial, before treatment, frequency of lymphocytes with micronuclei and treatment effectiveness, namely, the decreased number of damaged cells associated with the treatment efficiency, is very important for the treatment prognosis. The results obtained can be very important for the experimental justification and understanding a possible use of blood lymphocytes for the additional diagnostics of prostate gland cancer and prognosis for its successful treatment.
authors.forename: I I
authors.initials: II
authors.lastname: Pelevina
authors.forename: A V
authors.initials: AV
authors.lastname: Aleshchenko
authors.forename: M M
authors.initials: MM
authors.lastname: Antoshhina
authors.forename: V A
authors.initials: VA
authors.lastname: Biriukov
authors.forename: O B
authors.initials: OB
authors.lastname: Kariakin
authors.forename: O V
authors.initials: OV
authors.lastname: Kudriashova
authors.forename: M F
authors.initials: MF
authors.lastname: Nikonova
authors.forename: N G
authors.initials: NG
authors.lastname: Minaeva
authors.forename: A M
authors.initials: AM
authors.lastname: Serebrianyĭ
authors.forename: A A
authors.initials: AA
authors.lastname: Iarilin
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000097:blood; D000945:Antigens, Differentiation, T-Lymphocyte / Q000097:blood; D002467:Cell Nucleus / Q000528:radiation effects; D002869:Chromosome Aberrations / Q000528:radiation effects; D005720:Gamma Rays; D006801:Humans; D019394:Ki-67 Antigen / Q000097:blood; D037181:Lectins, C-Type / Q000097:blood; D008214:Lymphocytes / Q000473:pathology / Q000528:radiation effects*; D008297:Male; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology / Q000532:radiotherapy*; D011836:Radiation Tolerance; D011878:Radiotherapy / Q000009:adverse effects*; D017382:Reactive Oxygen Species / Q000528:radiation effects; D019014:fas Receptor / Q000097:blood; D000099192:CD69 Antigens
chemical_list: D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D019394:Ki-67 Antigen; D037181:Lectins, C-Type; D017382:Reactive Oxygen Species; D019014:fas Receptor; D000099192:CD69 Antigens